ARQTHealthcare · BiotechnologyThe 8 Wall Street analysts covering Arcutis Biotherapeutics, Inc. hold a median 12-month price target of $39 — +23.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 24 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Arcutis Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ARQT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.4% from it.
Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2026 | Guggenheim | Maintains | Buy | $38 → $44 |
| 15 Oct 2026 | Cantor Fitzgerald | Initiates | Overweight | $48 |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | $35 → $38 |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 6 Aug 2026 | Morgan Stanley | Maintains | Overweight | — |
| 6 Aug 2026 | Morgan Stanley | Maintains | Overweight | $34 → $38 |
| 6 Aug 2026 | Needham | Maintains | Buy | $36 → $40 |
| 6 Aug 2026 | Needham | Maintains | Buy | — |
| 7 May 2026 | Needham | Reiterates | Buy | $36 |
| 7 May 2026 | Needham | Reiterates | Buy | — |
| 2 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 27 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 26 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 26 Feb 2026 | Needham | Maintains | Buy | — |
| 26 Feb 2026 | TD Cowen | Maintains | Buy | — |
| 26 Jan 2026 | Needham | Maintains | Buy | — |
| 28 Nov 2025 | Mizuho | Maintains | Outperform | — |
| 30 Oct 2025 | Goldman Sachs | Maintains | Neutral | — |
| 28 Oct 2025 | Needham | Maintains | Buy | — |
| 7 Aug 2025 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ARQT appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, Arcutis Biotherapeutics, Inc. returned +55.4% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 5% of US stocks
Cheaper than 15% of US stocks
Cheaper than 5% of US stocks
Cheaper than 2% of US stocks
Higher than 88% of US stocks
Higher than 77% of US stocks
Higher than 97% of US stocks
Higher than 69% of US stocks
Higher than 63% of US stocks
Higher than 75% of US stocks
Higher than 77% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Arcutis Biotherapeutics, Inc. has a market value of $3.9B and an enterprise value of $3.8B.
Revenue in the twelve months to 30 June 2026: $464.0M. The latest quarter grew 59.3% year on year.
Net income over the same four quarters: $28.5M, a 6.1% net margin.
Diluted earnings per share, trailing twelve months: $0.21.
Free cash flow in the twelve months to 30 June 2026: $39.2M.
Trailing P/E: 141.8×; forward P/E: 23.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Arcutis Biotherapeutics, Inc. employs 354 people — $1.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Arcutis Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Arcutis announced it will report its third-quarter 2026 financial results and provide a business update after U.S. financial markets close on November 4, 2026.
Why it matters — ARQT watchers can note the date for the company’s quarterly results and business update.
Arcutis Biotherapeutics shares traded higher Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $48 price forecast. The firm cited strong Zoryve sales growth and dermatology expansion opportunities.
Why it matters — The coverage initiation and its cited growth drivers are relevant developments for ARQT watchers.
Arcutis presented data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants, alongside real-world topical corticosteroid research, at EADV and Fall Clinical.
Why it matters — The presentations provide updates on research involving Arcutis’s topical treatments, including investigational ZORYVE in infants.
Arcutis announced that ZORYVE (roflumilast) cream 0.15% received Marie Claire magazine’s 2026 “Best Prescription Skin Solution” Award. The newly created category recognizes innovation in prescription skin treatment; ZORYVE is indicated for mild to moderate atopic dermatitis in adults and children 6 years and older.
Why it matters — The award provides recognition for a ZORYVE formulation used to treat atopic dermatitis, a product relevant to Arcutis’s immuno-dermatology business.
Arcutis Biotherapeutics announced it granted an aggregate of 62,500 restricted stock units to six newly hired employees, approved by its Compensation Committee under the company's 2022 Inducement Plan with an October 1, 2026 grant date. The awards serve as a material inducement for the new hires' commencement of employment, in line with Nasdaq Listing Rule 5635(c)(4).
Why it matters — ARQT watchers may note this standard equity-based inducement grant, which signals new talent joining the company and is disclosed under Nasdaq listing requirements.
The 8 Wall Street analysts covering Arcutis Biotherapeutics, Inc. have a median 12-month price target of $39, with estimates ranging from $34 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Arcutis Biotherapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcutis Biotherapeutics, Inc. 81 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 24 Oct 2026, Arcutis Biotherapeutics, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +23.4% from the last close, and Ticker Nerd's factor model ranks Arcutis Biotherapeutics, Inc. 81 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Arcutis Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARQT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $48 over the next 12 months.
Arcutis Biotherapeutics, Inc. returned +55.4% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing and commercializing therapies for immune-mediated skin diseases.
The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026". Arcutis announced it will report its third-quarter 2026 financial results and provide a business update after U.S. financial markets close on November 4, 2026.
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing and commercializing therapies for immune-mediated skin diseases. The company’s portfolio centers on ZORYVE, a branded treatment platform that includes topical formulations used in conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and psoriasis in sensitive areas. Arcutis also advances a pipeline of dermatology candidates, including additional topical and systemic programs designed to address inflammatory skin disorders with high unmet medical need. Its research and development approach combines dermatology expertise with targeted drug development against biologically validated pathways, positioning the company as a specialist player in the medical dermatology market. Based in Westlake Village, California, Arcutis Biotherapeutics serves patients, dermatology clinicians, and healthcare providers through prescription therapies aimed at chronic skin conditions.
CEO Mr. Todd Franklin Watanabe M.A. · 354 employees · United States · https://www.arcutis.com
